Double autologous bone marrow transplantation for acute myelogenous leukemia in a patient treated for Hodgkin's disease
โ Scribed by Russell, J. A. ;Jones, A. R. ;Houwen, B. ;Poon, M.-C. ;Ruether, B. A.
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 373 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
โฆ Synopsis
A 30-year-old man developed acute myelogenous leukemia nearly 3 years after. treatment of Hodgkin's disease with radiation and three chemotherapy combinations. Remission was induced with one cycle of highdose Ara-C therapy. Three cycles of consolidation chemotherapy were given. The patient then had two autologous bone marrow transplants, the first after conditioning with 5 Gy total body irradiation, the second after Melphalan 140 mg/m'. The procedures were well tolerated, although hematolog-ical reconstitution was very slow after the second autotransplant. The patient has been disease-free for over 4 years. Such patients may be more vulnerable to transplant-related complications because of their previous exposure to chemotherapy and radiation, which may damage several organs including the bone marrow. This report demonstrates that patients with secondary acute myelogenous leukemia may tolerate a double autotransplant procedure and achieve durable rern issions.
๐ SIMILAR VOLUMES
A 32-year-old woman developed acute monocytic leukemia within a year of treatment for Hodgkin's disease with chemotherapy and radiation. Residual leukemia was present in the bone marrow after two induction courses of high-dose Ara-C. She received a bone marrow transplant from an HLA- and DR-identica
A nested case control study was carried out to investigate the association between treatment of patients with Hodgkin's disease (HD) and the risk of developing acute non-lymphocytic leukemia (ANLL). Seven Cancer Centers of the International Cancer Patient Data Exchange System of the UlCC participate
To the Editor: Relapse is still a problem for leukemias, particularly in the autologous bone marrow transplantation (ABMT) setting. Moreover, the CD20 positive phenotype, deยฎned as >20% expression, may be associated with a worse outcome [1]. Therefore, our experience with such a patient in whom we a